Figure 4.

Responder analyses. A, Proportions of dapagliflozin- and placebo-treated participants that had deterioration (>5-point worsening), no change, as well as small-moderate (5–<10 point), moderate-large (10–<20 point), and very large (≥20 point) improvements in Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS) at 12 weeks. B, Forest plot demonstrating the results of logistic regression models (adjusted for baseline KCCQ-CSS value, sex, estimated glomerular filtration rate, type 2 diabetes status, atrial fibrillation status, and ejection fraction [EF]), which compare the proportion of dapagliflozin- and placebo-treated patients who had deterioration, as well as at least small (≥5 point), at least moderate (≥10 point), and large (≥20 point) improvements in KCCQ-CSS (overall and stratified by EF).